{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T06:53:05Z","timestamp":1772347985383,"version":"3.50.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,6,10]],"date-time":"2023-06-10T00:00:00Z","timestamp":1686355200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,10]],"date-time":"2023-06-10T00:00:00Z","timestamp":1686355200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Takeda France"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:title>Abstract\n<\/jats:title><jats:p>Ixazomib (IXA) is an oral proteasome inhibitor (PI) used in combination with lenalidomide and dexamethasone (IXA-Rd) for patients with relapsed and\/or refractory multiple myeloma (RRMM). The REMIX study is one of the largest prospective, real-world analysis of the effectiveness of IXA-Rd in the setting of RRMM. Conducted in France between August 2017 and October 2019, the REMIX study, a non-interventional prospective study, included 376 patients receiving IXA-Rd in second line or later and followed for at least 24\u00a0months. Primary endpoint was the median progression-free survival (mPFS). Median age was 71\u00a0years (Q1-Q3 65.0 \u2013 77.5) with 18.4% of participants older than 80\u00a0years. IXA-Rd was initiated in L2, L3 and L4\u2009+\u2009for 60.4%, 18.1% and 21.5%, respectively. mPFS was 19.1\u00a0months (95% CI [15.9, 21.5]) and overall response rate (ORR) was 73.1%. mPFS was 21.5, 21.9 and 5.8\u00a0months in patients receiving IXA-Rd as L2, L3, L4\u2009+\u2009respectively. Among patients receiving IXA-Rd in L2 and L3, mPFS was similar for patients previously exposed to lenalidomide (19.5\u00a0months) than for those lenalidomide naive (not exposed, 22.6\u00a0months, <jats:italic>p<\/jats:italic>\u2009=\u20090.29). mPFS was 19.1\u00a0months in patients younger than 80\u00a0years and 17.4\u00a0months in those 80\u00a0years or older (<jats:italic>p<\/jats:italic>\u2009=\u20090.06) with similar ORR (72.4% and 76.8%) in both subgroups. Adverse events (AEs) were reported in 78.2% of patients including 40.7% of treatment-related AE. IXA discontinuation was due to toxicity in 21% of patients.\u00a0To conclude, the results of the REMIX study are consistent with the results of Tourmaline-MM1 and confirm the benefit of IXA-Rd combination in real life. It shows the interest of IXA-Rd in an older and frailer population, with an acceptable effectiveness and tolerance.<\/jats:p>","DOI":"10.1007\/s00277-023-05278-3","type":"journal-article","created":{"date-parts":[[2023,6,10]],"date-time":"2023-06-10T16:01:33Z","timestamp":1686412893000},"page":"2137-2151","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Real-world effectiveness of ixazomib combined with lenalidomide and dexamethasone in relapsed\/refractory multiple myeloma: the REMIX study"],"prefix":"10.1007","volume":"102","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0460-0658","authenticated-orcid":false,"given":"M.","family":"Macro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Hulin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Vincent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Charvet-Rumpler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Benboubker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Calmettes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.-M.","family":"Stoppa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Laribi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Clement-Filliatre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Zerazhi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Honeyman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Richez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Maloisel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Karlin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Barrak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Chouaid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"X.","family":"Leleu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,6,10]]},"reference":[{"key":"5278_CR1","doi-asserted-by":"publisher","first-page":"5419","DOI":"10.1158\/1078-0432.CCR-16-0625","volume":"22","author":"KC Anderson","year":"2016","unstructured":"Anderson KC (2016) Progress and paradigms in multiple myeloma. Clin Cancer Res Off J Am Assoc Cancer Res 22:5419\u20135427","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"5278_CR2","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1080\/17474086.2017.1285694","volume":"10","author":"J-S Boudreault","year":"2017","unstructured":"Boudreault J-S, Touzeau C, Moreau P (2017) Triplet combinations in relapsed\/refractory myeloma: update on recent phase 3 trials. Expert Rev Hematol 10:207\u2013215","journal-title":"Expert Rev Hematol"},{"key":"5278_CR3","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","volume":"32","author":"MA Dimopoulos","year":"2021","unstructured":"Dimopoulos MA, Moreau P, Terpos E et al (2021) Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up\u2020. Ann Oncol Off J Eur Soc Med Oncol 32:309\u2013322","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"5278_CR4","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","volume":"374","author":"P Moreau","year":"2016","unstructured":"Moreau P, Masszi T, Grzasko N et al (2016) Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 374:1621\u20131634","journal-title":"N Engl J Med"},{"key":"5278_CR5","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25134","author":"X Leleu","year":"2018","unstructured":"Leleu X, Masszi T, Bahlis NJ et al (2018) Patient-reported health-related quality of life from the phase III TOURMALINE-MM1 study of ixazomib-lenalidomide-dexamethasone versus placebo-lenalidomide-dexamethasone in relapsed\/refractory multiple myeloma. Am J Hematol. https:\/\/doi.org\/10.1002\/ajh.25134","journal-title":"Am J Hematol"},{"key":"5278_CR6","first-page":"423","volume":"11","author":"J Willan","year":"2016","unstructured":"Willan J, Eyre TA, Sharpley F, Watson C, King AJ, Ramasamy K (2016) Multiple myeloma in the very elderly patient: challenges and solutions. Clin Interv Aging 11:423\u2013435","journal-title":"Clin Interv Aging"},{"key":"5278_CR7","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1097\/CCO.0000000000000395","volume":"29","author":"S Zweegman","year":"2017","unstructured":"Zweegman S, Engelhardt M, Larocca A, EHA SWG on \u2018Aging and Hematology\u2019 (2017) Elderly patients with multiple myeloma: towards a frailty approach? Curr Opin Oncol 29:315\u2013321","journal-title":"Curr Opin Oncol"},{"key":"5278_CR8","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.critrevonc.2019.02.011","volume":"137","author":"MA Fraz","year":"2019","unstructured":"Fraz MA, Warraich FH, Warraich SU et al (2019) Special considerations for the treatment of multiple myeloma according to advanced age, comorbidities, frailty and organ dysfunction. Crit Rev Oncol Hematol 137:18\u201326","journal-title":"Crit Rev Oncol Hematol"},{"key":"5278_CR9","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.clml.2017.06.013","volume":"17","author":"JJ Shah","year":"2017","unstructured":"Shah JJ, Abonour R, Gasparetto C et al (2017) Analysis of common eligibility criteria of randomized controlled trials in newly diagnosed multiple myeloma patients and extrapolating outcomes. Clin Lymphoma Myeloma Leuk 17:575-583.e2","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"5278_CR10","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1182\/blood-2019-125749","volume":"134","author":"VTM Hungria","year":"2019","unstructured":"Hungria VTM, Lee HC, Abonour R et al (2019) Real-world (RW) multiple myeloma (MM) patients (Pts) remain under-represented in clinical trials based on standard laboratory parameters and baseline characteristics: analysis of over 3,000 Pts from the Insight MM Global, Prospective, Observational Study. Blood 134:1887","journal-title":"Blood"},{"key":"5278_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.09.625","author":"A Chari","year":"2019","unstructured":"Chari A, Romanus D, Palumbo A, Blazer M, Farrelly E, Raju A, Huang H, Richardson P (2019) Randomized clinical trial representativeness and outcomes in real-world patients: comparison of 6 hallmark RCTs in relapsed\/refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. https:\/\/doi.org\/10.1016\/j.clml.2019.09.625","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"5278_CR12","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1182\/blood-2014-12-615187","volume":"125","author":"A Palumbo","year":"2015","unstructured":"Palumbo A, Bringhen S, Mateos M-V et al (2015) Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. Blood 125:2068\u20132074","journal-title":"Blood"},{"key":"5278_CR13","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.jgo.2017.09.007","volume":"9","author":"P Hari","year":"2018","unstructured":"Hari P, Romanus D, Luptakova K, Blazer M, Yong C, Raju A, Farrelly E, Labotka R, Morrison VA (2018) The impact of age and comorbidities on practice patterns and outcomes in patients with relapsed\/refractory multiple myeloma in the era of novel therapies. J Geriatr Oncol 9:138\u2013144","journal-title":"J Geriatr Oncol"},{"key":"5278_CR14","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1007\/s00277-021-04534-8","volume":"100","author":"F Davies","year":"2021","unstructured":"Davies F, Rifkin R, Costello C et al (2021) Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed\/refractory multiple myeloma (RRMM) in the US. Ann Hematol 100:2325\u20132337","journal-title":"Ann Hematol"},{"key":"5278_CR15","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1080\/17474086.2020.1729734","volume":"13","author":"A Chari","year":"2020","unstructured":"Chari A, Richardson PG, Romanus D et al (2020) Real-world outcomes and factors impacting treatment choice in relapsed and\/or refractory multiple myeloma (RRMM): a comparison of VRd, KRd, and IRd. Expert Rev Hematol 13:421\u2013433","journal-title":"Expert Rev Hematol"},{"key":"5278_CR16","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A et al (2014) International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 15:e538-548","journal-title":"Lancet Oncol"},{"key":"5278_CR17","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1038\/s41375-019-0539-0","volume":"34","author":"T Facon","year":"2020","unstructured":"Facon T, Dimopoulos MA, Meuleman N et al (2020) A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial. Leukemia 34:224\u2013233","journal-title":"Leukemia"},{"key":"5278_CR18","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","volume":"310","author":"World Medical Association","year":"2013","unstructured":"World Medical Association (2013) World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 310:2191\u20132194","journal-title":"JAMA"},{"key":"5278_CR19","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1002\/pds.1082","volume":"14","author":"M Epstein","year":"2005","unstructured":"Epstein M, International Society of Pharmacoepidemiology (2005) Guidelines for good pharmacoepidemiology practices (GPP). Pharmacoepidemiol Drug Saf 14:589\u2013595","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"5278_CR20","unstructured":"Official Journal of the European Communities (1995) Directive 95\/46\/EC of the European parliament and of the council of 24 october 1995 on the protection of individuals with regard to the processing of personal data and on the free movement of such data. 281"},{"key":"5278_CR21","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1007\/s12253-019-00607-2","volume":"25","author":"G Varga","year":"2019","unstructured":"Varga G, Nagy Z, Demeter J et al (2019) Real world efficacy and safety results of ixazomib lenalidomide and dexamethasone combination in relapsed\/refractory multiple myeloma: data collected from the Hungarian ixazomib named patient program. Pathol Oncol Res POR 25:1615\u20131620","journal-title":"Pathol Oncol Res POR"},{"key":"5278_CR22","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1007\/s00277-020-03985-9","volume":"99","author":"YC Cohen","year":"2020","unstructured":"Cohen YC, Magen H, Lavi N et al (2020) Ixazomib-based regimens for relapsed\/refractory multiple myeloma: are real-world data compatible with clinical trial outcomes? A multi-site Israeli registry study. Ann Hematol 99:1273\u20131281","journal-title":"Ann Hematol"},{"key":"5278_CR23","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1007\/s00277-020-03981-z","volume":"99","author":"E Terpos","year":"2020","unstructured":"Terpos E, Ramasamy K, Maouche N et al (2020) Real-world effectiveness and safety of ixazomib-lenalidomide-dexamethasone in relapsed\/refractory multiple myeloma. Ann Hematol 99:1049\u20131061","journal-title":"Ann Hematol"},{"key":"5278_CR24","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s12885-020-07732-1","volume":"21","author":"J Minarik","year":"2021","unstructured":"Minarik J, Pika T, Radocha J et al (2021) Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice. BMC Cancer 21:73","journal-title":"BMC Cancer"},{"key":"5278_CR25","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.2217\/fon-2020-1225","volume":"17","author":"R H\u00e1jek","year":"2021","unstructured":"H\u00e1jek R, Mina\u0159\u00edk J, Straub J et al (2021) Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed\/refractory multiple myeloma. Future Oncol Lond Engl 17:2499\u20132512","journal-title":"Future Oncol Lond Engl"},{"key":"5278_CR26","doi-asserted-by":"publisher","unstructured":"Richardson PG, Kumar SK, Masszi T, Grzasko N, Bahlis NJ, Hansson M, Pour L, Sandhu I, Ganly P, Baker BW, Jackson SR, Stoppa AM, Gimsing P, Garderet L, Touzeau C, Buadi FK, Laubach JP, Cavo M, Darif M, Labotka R, Berg D, Moreau P (2021) Final overall survival analysis of the tourmaline-mm1 phase iii trial of ixazomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma. J Clin Oncol 39(22):2430\u20132442. https:\/\/doi.org\/10.1200\/JCO.21.00972","DOI":"10.1200\/JCO.21.00972"},{"key":"5278_CR27","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1038\/s41375-019-0435-7","volume":"33","author":"UH Gandhi","year":"2019","unstructured":"Gandhi UH, Cornell RF, Lakshman A et al (2019) Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia 33:2266\u20132275","journal-title":"Leukemia"},{"key":"5278_CR28","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.3324\/haematol.2017.170118","volume":"102","author":"M-V Mateos","year":"2017","unstructured":"Mateos M-V, Masszi T, Grzasko N et al (2017) Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone vs. placebo-lenalidomide-dexamethasone in patients with relapsed\/refractory multiple myeloma in TOURMALINE-MM1. Haematologica 102:1767\u20131775","journal-title":"Haematologica"},{"key":"5278_CR29","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1111\/bjh.14733","volume":"178","author":"S Kumar","year":"2017","unstructured":"Kumar S, Moreau P, Hari P et al (2017) Management of adverse events associated with ixazomib plus lenalidomide\/dexamethasone in relapsed\/refractory multiple myeloma. Br J Haematol 178:571\u2013582","journal-title":"Br J Haematol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05278-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-023-05278-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05278-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,13]],"date-time":"2023-07-13T07:06:59Z","timestamp":1689232019000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-023-05278-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,10]]},"references-count":29,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["5278"],"URL":"https:\/\/doi.org\/10.1007\/s00277-023-05278-3","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,10]]},"assertion":[{"value":"20 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the ethical principles of the Declaration of Helsinki, the principles of the International Society for Pharmacoepidemiology guidelines for Good Pharmacoepidemiology Practice, and in compliance with the General Data Protection Regulation (GDPR). Approval was granted by the French Ethics Committee of Clermont-Ferrand (CPP SUD-EST VI) on November 9th, 2017 (N\u00b0 AU 1381).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"MM has received Honoraria from Janssen, Sanofi, GSK and Takeda, travel support from Janssen and Takeda and research funding from Janssen and Takeda. CH has received honoraria from Janssen, BMS, GSK, Takeda, Sanofi and Amgen. LV has been a member on an entity\u2019s board of directors or advisory committee for BMS, Janssen and Takeda, received honoraria from Janssen and Sanofi and funding for meeting participation for BMS, Janssen, Takeda, Sanofi and Pfizer. KL has received honoraria from AbbVie, AstraZeneca, Beigene, Iqone, Janssen, Novartis and Takeda. LK has received travel support from Janssen. JB is a Takeda employee. CC has been consultant for Amgen, AstraZeneca and Roche and has received honoraria and research funding for Amgen, AstraZeneca, BMS, GSK, Merck, Novartis, Pfizer, Roche and Takeda. XL is a consultant and has received honoraria from Amgen, Merck, BMS, GSK, Janssen, Oncopeptide, Takeda, Roche, Novartis, AbbVie, Sanofi, Gilead, Pfizer, Harpoon Therapeutic, Regeneron and Iteos. The other authors declare they have no financial interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}